Document number: PSM Haematology Issue number: 3.02	Effective date: 22/09/2023	Page 1 of 17
Title: Primary Sample Manual - Haematology		


Author: Marcus Kenyon

Approved By: Dr. P. Hayden, Charles Aguegwu, Sampada Kulkarni

Title: Primary Sample Manual - Haematology

Changes made since previous version: Non fasting reference removed. Updated for MPV. Removed reference to accreditation and testing location.

Note: Please refer to the document record on QPulse for the revision history of this document.



Document number: PSM Effective date: Page 2 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

CONTENTS

FULL BLOOD COUNT (FBC)	3
ERYTHROCYTE SEDIMENTATION RATE (ESR)	7
INFECTIOUS MONONUCLEOSIS	8
FIBRINOGEN (CLAUSS METHOD)	. 10
PROTHROMBIN TIME (PT)	. 11
ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)	. 12
BLOOD PARASITOLOGY - MALARIA	. 14
D-DIMER	. 15
RETICULOCYTES	. 16
SICKLE CELL SCREENING TEST	. 17

HAEMATOLOGY CONSULTANT RESPONSIBLE: Dr. Patrick Hayden EUROFINS BIOMNIS: +353-1-295-8545

Document number: PSM Haematology Issue number: 3.02	Effective date: 22/09/2023	Page 3 of 17
Title: Primary Sample Manual - Haematology		

FULL BLOOD COUNT (FBC)

The Full Blood Count (FBC) is one of the most commonly requested laboratory tests and is a very useful indicator of potential problems that require further investigation. Common causes of an abnormal RCC & haematocrit include anaemia, acute blood loss & polycythaemia. Depressed WCC may be seen in AIDS, cancer and overwhelming infections. High WCCs are commonly observed in leukaemia and infections. A high neutrophil count often indicates an infection. A low lymphocyte count can be seen in AIDS patients. A high monocyte count can indicate a bacterial infection and a high eosinophil count indicates an allergic reaction or a parasitic infection. Common causes of a low platelet count include immune system disorders, some leukaemias and patients undergoing cancer treatments.

Preparation of patients: There is no physical preparation for the FBC test. **Precautions:** Frozen, clotted, or grossly haemolysed samples cannot be analysed.

Accredited	No			
Method	Sysmex XN2000	Sysmex XN1000		
	SOP: H57	SOP: BH09		
Sample Requirements	Tube Type: Whole Blood EDTA	Tube Type: Whole Blood EDTA		
	Temperature: + 4°C	Temperature: + 4°C		
	Miscellanous: N/A	Miscellanous: N/A		
Turn Around Time – Setup	Mon Tue Wed Thu Fri Sat	Mon Tue Wed Thu Fri Sat		
Schedule		\checkmark \checkmark \checkmark \checkmark		
	24h	24h		
Stability	2 days @ + 4°C			

eurofins 🙀

Document number: PSM Effective date: Page 4 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

FBC Adult Reference Ranges

Units -Reference Ranges

	1
Analyte	Units Of Measurement
WBC	10^9/L
RBC	10^12/L
НВ	g/dL
HCT	L/L
MCV	fL
MCH	pg
MCHC	g/dL
PLT	10^9/L
MPV	fL
RDW	%
#Neut	10^9/L
#Lymph	10^9/L
#Mono	10^9/L
#Eos	10^9/L
#Baso	10^9/L

Source

Adult Reference Range		
Male	Female	
4.0 - 10.0	4.0 - 10.0	
4.5 - 5.5	3.8 - 4.8	
13.0 - 17.0	12.0 - 15.0	
0.400 - 0.500	0.360 - 0.460	
83 -101	83 - 101	
27 - 32	27 - 32	
31.5 - 34.5	31.5 - 34.5	
150 - 410	150 - 410	
N/A	N/A	
11.6 - 14.0	11.6-14.0	
2.0 – 7.0	2.0 – 7.0	
1.0 – 3.0	1.0 – 3.0	
0.2 – 1.0	0.2 – 1.0	
0.02 - 0.50	0.02 - 0.50	
0.02 - 0.10	0.02 - 0.10	

Dacie and Lewis, Practical Haematology 12th edition, 2017

Document number: PSM	Effective date:	Page 5 of 17
Haematology	22/09/2023	
Issue number: 3.02		
	Title:	
Primary Sample Manual - Haematology		

FBC Paediatric Reference Ranges

Units - Reference Ranges		Paediatric Reference Ranges	
Analytes	Units of Measurement	Male	Female
WBC	10^9/L	Up to 1 year (6.00-16.00) Up to 6 years (5.00-15.00) Up to 12 years (5.00-13.00) Up to 18 years (3.88-10.49)	
RBC	10^12/L	Up to 1 year (3.90-5.10) Up to 12 years (4.00-5.20) Up to 18 years (4.28-5.59)	Up to 1 year (3.90-5.10) Up to 12 years (4.00-5.20) Up to 18 years (3.73-5.02)
НВ	g/dL	Up to 1 year (11.1-14.1) Up to 6 years (11.0-14.0) Up to 12 years (11.5-15.5) Up to 18 years (13.5-17.2)	Up to 1 year (11.1-14.1) Up to 6 years (11.0-14.0) Up to 12 years (11.5-15.5) Up to 18 years (11.3-15.2)
HCT	L/L	Up to 1 year (0.300-0.380) Up to 6 years (0.340-0.400) Up to 12 years (0.350-0.450) Up to 18 years (0.381-0.499)) Ψp to 12 years (0.350-0.450)
MCV	fL	Up to 1 year (72.0-84.0) Up to 6 years (75.0-87.0) Up to 12 years (77.0-95.0) Up to 18 years (83.1-99.1)	Up to 1 year (72.0-84.0) Up to 6 years (75.0-87.0) Up to 12 years (77.0-95.0) Up to 18 years (83.1-99.1)
MCH	Pg	Up to 1 year (25.0-29.0) Up to 6 years (24.0-30.0) Up to 12 years (25.0-33.0) Up to 18 years (28.3-33.9)	Up to 1 year (25.0-29.0) Up to 6 years (24.0-30.0) Up to 12 years (25.0-33.0) Up to 18 years (28.3-33.9)
MCHC	g/dL	Up to 1 year (32.0-36.0) Up to 6 years (31.0-37.0) Up to 12 years (31.0-37.0) Up to 18 years (32.1-36.6)	Up to 1 year (32.0-36.0) Up to 6 years (31.0-37.0) Up to 12 years (31.0-37.0) Up to 18 years (32.1-36.6)
PLT	10^9/L	Up to 1 year (200-550) Up to 6 years (200-490) Up to 12 years (170-450) Up to 18 years (164-382)	Up to 1 year (200-550) Up to 6 years (200-490) Up to 12 years (170-450) Up to 18 years (164-382
RDW	%	No separate paediatric rang	No separate paediatric ranges

THIS DOCUMENT IS CONTROLLED. PRINTED DOCUMENTS ARE DEEMED CONTROLLED WHEN STAMPED 'IF THIS IS GREEN IT IS AN APPROVED ISSUE'.



Document number: PSM Effective date: Page 6 of 17
Haematology 22/09/2023
Issue number: 3.02
Title:
Primary Sample Manual - Haematology

#Neut	10^9/L	Up to 1 year (1.00-7.000 Up to 6 years (1.50-8.00) Up to 12 years (2.00-8.00) Up to 18 years (1.56-6.52)	Up to 1 year (1.00-7.000 Up to 6 years (1.50-8.00) Up to 12 years (2.00-8.00) Up to 18 years (1.56-6.52)
#Lymph	10^9/L	Up to 1 year (3.50-11.00) Up to 6 years (6.00-9.00) Up to 12 years (1.00-5.00) Up to 18 years (1.01-3.13)	Up to 1 year (3.50-11.00) Up to 6 years (6.00-9.00) Up to 12 years (1.00-5.00) Up to 18 years (1.01-3.13)
#Mono	10^9/L	Up to 1 year (0.20-1.00) Up to 6 years (0.20-1.00) Up to 12 years (0.20-1.00) Up to 18 years (1.01-3.13)	Up to 1 year (0.20-1.00) Up to 6 years (0.20-1.00) Up to 12 years (0.20-1.00) Up to 18 years (1.01-3.13)
#Eos	10^9/L	Up to 12 years (0.10-1.00) Up to 18 years (0.05-0.51)	Up to 12 years (0.10-1.00) Up to 18 years (0.05-0.51)
#Baso	10^9/L	Up to 1 day (0.00-0.64) Up to 7 days (0.00-0.25) Up to 14 years (0.00-0.23) Up to 18 years (0.02-0.15)	Up to 1 day (0.00-0.64) Up to 7 days (0.00-0.25) Up to 14 years (0.00-0.23) Up to 18 years (0.02-0.15)
Source	Dacie and Lewis, Practical Haematology 12th edition, 2017		

Document number: PSM Effective date: Page 7 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

ERYTHROCYTE SEDIMENTATION RATE (ESR)

The Erythrocyte Sedimentation Rate (ESR) is a traditional test used in Haematology. It is affected by the numbers of erythrocytes present in the blood, changes in plasma protein pattern, age and sex of the patient. Three phases can be distinguished in the sedimentation process: the lag phase (reflects the period in which the individual erythrocytes form rouleaux), the decantation or precipitation phase (the plasma-red cell interface falls more rapidly), and the final packing phase (the red cells aggregates pile up on the bottom of container). The ESR is dependent on the presence of agglomers, such as fibrinogen, IgM, alpha2-macroglobulin and other acute phase proteins. It is a completely non-specific test. It is a measure of the presence and severity of pathological processes. In general, the ESR is elevated in all acute, general infections, in localized, acute, inflammatory conditions, variations in the ESR depend on the nature and severity of the process. Additionally, the ESR is an important screen for occult disease. The ESR is also useful to differentiate organic disease from functional disorders, or as a guide to the progress of diseases such as rheumatic carditis, rheumatoid arthritis, and certain malignancies, including Hodgkin's disease, and is diagnostic for Temporal Arteritis.

Preparation of patients: There is no physical preparation for the ESR test.

Precautions: The ESR should not be used to screen healthy persons for disease.

Frecautions.	-recautions: The LSIX should not be used to screen healthy persons for disease.					
Accredited	No			No		
Method	Haematology – Capillary		Westergren manual method using S-			
	photometric-kinetic to	echnolo	ogy	Sedivette tubes		
	SOP: H9			SOP: BH04		
Sample	Tube Type: Whole B	lood (L	.avender	Tube Type: Whole Blo	od (Laven	ider cap)
Requirements	cap)			Temperature: + 4°C		
	Temperature: + 4°C			Miscellanous: N/A		
	Miscellanous: N/A					
Turn Around	Mon Tue Wed	Thu	Fri Sat	Mon Tue Wed T	hu Fri	Sat
Time - Setup	√ √ √	✓	√ √	✓ ✓ ✓ ✓	′ √	√
Schedule						
	24h					
				24h		
Stability	2 days @ + 4°C		24 hours @ + 4°C			
	•					
Units -	mm/hr			mm/hr		
Reference	ESR Ref	Male	Female		Male	Female
Ranges	Ranges			ESR Ref Ranges	0-10	2-20
	>50 Years	0-≤12	0-≤15			
	<50 Years	0-≤8	0-≤10			
Source	Reference ranges for	or the E	SR assay	Dacie and Lewis, Prac	tical Haen	natology
	are derived in ho	use. I	Data was	12th edition, 2017		
	obtained from a	clinica	al normal			
	population and statistics generated					
	using the Graph Pad statistics					
	doing the Chapit					
	module. Data was					
		s ana	llysed for			
	module. Data was	s ana	llysed for reference			
	module. Data was Gaussian distributio	s ana n and using	llysed for reference			
	module. Data was Gaussian distributio ranges derived	s ana n and using non-	llysed for reference g either parametric			

🧱 eurofins

Document number: PSM Haematology Issue number: 3.02	Effective date: 22/09/2023	Page 8 of 17
Title: Primary Sample Manual - Haematology		

INFECTIOUS MONONUCLEOSIS

Infectious mononucleosis (glandular fever) is an acute infectious disease caused by the Epstein-Barr virus and primarily affects lymphoid tissue. It is characterized by the appearance of enlarged and often tender lymph nodes, enlarged spleen, and abnormal lymphocytes in the blood. Patients usually, but not always, develop a transient heterophile antibody response.

The detection of heterophile antibodies of Infectious Mononucleosis by the agglutination of sheep red cells was first reported by Paul and Bunnel. Subsequent work identified the need for differential absorption of sera to remove non-infectious mononucleosis heterophile antibodies. Fetcher and Woolfolk showed that antigens obtained from bovine erythrocytes were more effective than those antigens obtained from either sheep or horse erythrocytes.

Preparation of patients: There is no physical preparation for the infectious mononucleosis test.

Precautions: IgG and IgM values obtained with different manufacturers' assay methods may not be used interchangeably. The magnitude of the reported IgG or IgM level cannot be correlated to an endpoint titre.

Accredited	No
Method	Haematology- Immunoassay SOP: H20
Sample Requirements	Tube Type: Whole blood serum or plasma Temperature: + 4°C Miscellaneous: N/A
Turn Around Time – Setup Schedule	24h Mon Tue Wed Thu Fri
Stability	3 days @ + 4°C
Result	Positive or negative
Source	'Clearview IM II' Kit Insert, Alere group.

eurofins 🙀

Document number: PSM Haematology Issue number: 3.02	Effective date: 22/09/2023	Page 9 of 17		
Title: Primary Sample Manual - Haematology				

SAMPLE REQUIREMENTS FOR COAGULATION TESTS

PROCEDURE

Sample Requirements and Collection

- Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase FVIII, vWF antigen and fibrinolysis. Venous occlusion should be avoided.
- Difficult venepuncture with trauma may lead to platelet activation with release of PF4 from alpha granules.
- Venous blood should be collected into coagulation tubes containing Sodium Citrate 3.2%, 0.105M, 3ml.
- Specimens must be mixed immediately post venepuncture to avoid clot activation, by GENTLY inverting the tubes 5 to 10 times.
- > The ratio of whole blood to anticoagulant is crucial. Under-filled specimens will not be processed as over- or under-filled tubes can adversely affect results.
- Any warfarin treatment should be mentioned on the request form.

Transportation and Storage

- ➤ PT/INR specimens should ideally be analysed within 12 hours of collection and transported to the laboratory at room temperature.
- ➤ APTT and Fibrinogen should ideally be analysed within 4 hours of collection. Where this is not possible please centrifuge at room temperature (RT) @3000rpm (1500g) for at least 15 minutes, and then carefully remove the plasma from the cells, transfer to a fresh plastic plain tube and freeze at -20°C.
- ➤ Non-frozen coagulation specimens should be transported at RT ASAP to avoid deterioration of labile factors V and VIII.
- Collection of blood through intravenous lines that have been previously flushed with heparin should be avoided. In the event blood is drawn from an indwelling catheter, the line should be flushed with 5ml of saline, and the first 5ml of blood or 6 times the line volume be drawn off and discarded before coagulation tube is filled.

Plasma Sample Stability (CLSI H21-A5)

- > PT 24 hours @ RT or 2 weeks @-20°C
- APTT 4 hours @ RT or 2 weeks @-20°C & 12 Months @-70°C
- Fibrinogen- 4 hours @ RT

Document number: PSM	Effective date:	Page 10 of 17		
Haematology	22/09/2023			
Issue number: 3.02				
Title:				
Primary Sample Manual - Haematology				

FIBRINOGEN (CLAUSS METHOD)

Clauss developed a simple method for the quantitative determination of Fibrinogen by measuring the clotting time of dilute plasma after the addition of Thrombin. The clotting time is inversely proportional to the Fibrinogen concentration. The clotting time obtained in this manner is then compared with that of a standardised Fibrinogen preparation. The plasma must be diluted to provide a low level of potential inhibitors, e.g. FDP's and Heparin. A strong Thrombin solution is utilised in order to ensure that the clotting time is independent of Thrombin concentration over a broad range.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Veno-occlusion should be avoided.

Precautions: This test is not recommended for patients with active bleeding, acute infection or illness, or in those patients who have received blood transfusions within four weeks. Drugs that may increase Fibrinogen levels include Oestrogens and oral contraceptives. Drugs that may cause decreased levels include anabolic steroids, androgens, Phenobarbital, Urokinase, Streptokinase, and Valproic acid.

Accredited	No	No		
Method	Stago Compact Max, Stago Satellite Max	Sysmex CA660		
	SOP: H60, H56	SOP: BH05 and BH08		
Sample	Tube Type: Sodium Citrate Plasma 3.2%	Tube Type: Sodium Citrate Plasma 3.2%		
Requirements	0.105M	0.105M		
	Temperature : 4 hours Room temperature	Temperature : 4 hours Room temperature		
	or 2 weeks @ -20°C.	or 2 weeks @ -20°C.		
	If an expected delay in transporting	If an expected delay in transporting		
	samples to the laboratory samples should	samples to the laboratory samples should		
	be centrifuge, separated & send as frozen within 4 hours of blood collection.	be centrifuge, separated & send as frozen within 4 hours of blood collection.		
	Miscellaneous: N/A	Miscellaneous: N/A		
	Collection: Cf. Special requirement for	Collection: Cf. Special requirement for		
	Coagulation test	Coagulation test		
Turn Around	24h	24h		
Time - Setup	Mon Tue Wed Thu Fri	Mon Tue Wed Thu Fri		
Schedule	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
Stability	Whole blood: 4 hours, unless centrifuged	Whole blood: 4 hours, unless centrifuged at		
	at room temperature at 1500g, separated	room temperature at 1500g, separated and		
	and the plasma frozen. Can only be	the plasma frozen. Can only be thawed		
	thawed once. If an expected delay from	once. If an expected delay from collection		
	collection time to receipt in the laboratory,	time to receipt in the laboratory, suggest		
	suggest send frozen sample.	send frozen sample.		
	(SIEMENS Kit Insert & CSLI H21-A5)	(SIEMENS Kit Insert & CSLI H21-A5)		
Units -	1.8 – 3.6 g/L	1.69 – 3.09 g/L		
Reference				
Ranges				
Source	Dacie and Lewis, Practical Haematology	Coagulation reference ranges were based		
	12th edition, 2017	on values obtained by analysis of 50		
		samples from healthy adult plasma donors		

Document number: PSM Effective date: Page 11 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

PROTHROMBIN TIME (PT)

The PT test (scientific name- tissue activated induced coagulation time) has been in clinical practice for over 60 years. The first standardised one-stage PT test was devolved by Dr. Armand Quick in 1932. It has now become the basic coagulation screening test for the diagnosis of acquired and congenital deficiencies of clotting factors in the Extrinsic pathway. The assay was designed to measure a coagulation defect before the introduction of oral anticoagulants, and later adapted for monitoring their dosage. The PT reflects changes in the Extrinsic factors II, VII and X, three of the principle clotting factors depressed by Coumarin drugs, and FV, not reduced by oral anticoagulation. It can also be used to assess the protein synthesis capability of the liver in chronic or acute hepatic disorders. The test depends on the activation of Factor X in the presence of Factor VII by Tissue Factor (TF) and bypassing of the Intrinsic clotting pathway. The speed of the reaction and the responsiveness of the PT to deficiencies of clotting factors depend upon the properties and concentration of the TF as well as on the clotting factor concentrations.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Veno-occlusion should be avoided.

Precautions: The doctor should check to see if the patient is taking any medications that may affect test results. This precaution is particularly important if the patient is taking Warfarin, because there are a number of medications that can interact with Warfarin to increase or decrease the PT time.

icalcations that can interact with wanta			
No	No		
Stago Compact Max, Stago Satellite	Sysmex CA660		
	SOP: BH05 and BH07		
, ,	Tube Type: Sodium Citrate Plasma 3.2%		
	0.105M		
0.270 01.100	Temperature:12 hours Room		
•	Temperature or 2 weeks @ -20°C		
	Miscellaneous: N/A		
	Collection: Cf. Special requirement for		
	Coagulation test		
Mon Tue Wed Thu Fri	24h Mon Tue Wed Thu Fri		
√ √ √ √	√ √ √ √		
Whole blood: 12 hours at room	Whole blood: 12 hours at room		
temperature. If a longer delay is	temperature. If a longer delay is expected		
	in transport to the laboratory, centrifuge at		
	1500g for at least 15 minutes, separate,		
	and freeze plasma. Can only be thawed		
	once.		
	(SIEMENS Kit Insert & CSLI H21-A5)		
1 000.	(SIZINZINO NICINOSICA COZITIZI AO)		
· ·			
,	PT 10.1 – 11.7 Seconds		
	INR 0.94 - 1.10		
Ι ΙΝΙΧ ΙΝΟΙ αρριισασίο	11417 0.07 - 1.10		
Dacie and Lewis, Practical	Coagulation reference ranges were based		
	on values obtained by analysis of 50		
	samples from healthy adult plasma		
	donors		
	Stago Compact Max, Stago Satellite Max SOP: H60, H56 Tube Type: Sodium Citrate Plasma 3.2% 0.105M Temperature:12 hours Room Temperature or 2 weeks @ -20°C Miscellaneous: N/A Collection: Cf. Special requirement for Coagulation test 24h Mon Tue Wed Thu Fri V V V V Whole blood: 12 hours at room temperature. If a longer delay is expected in transport to the laboratory, centrifuge at 1500g for at least 15 minutes, separate, and freeze plasma. Can only be thawed once. (SIEMENS Kit Insert & CSLI H21-A5) PT 11.0 – 16.0 Seconds INR – Not applicable		

🧱 eurofins

Document number: PSM Effective date: Page 12 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

This test is also known as the Partial Thromboplastin Time with Kaolin (PTTK) and the Kaolin Cephalin Clotting Time (KCCT) reflecting the methods used to perform the test. The APTT is the main screening test for the Intrinsic clotting system and is the second most common coagulation test being exceeded in frequency only by the prothrombin time.

The Partial Thromboplastin of the APTT is a phospholipid extract of animal tissue or from vegetable sources. The phospholipids act as a platelet substitute in the Intrinsic system. The test incorporates an activator, in the absence of added Thromboplastin, which shortens the test and increases the precision and reproducibility by eliminating the variable effects of contact from glass surfaces and by effecting maximum activation. The activator is used to stimulate the production of FXIIa by providing a surface for the function of high molecular weight Kininogen, Kallikrein and FXIIa. The contact activation occurs for a time at 37°C. Calcium is then added to trigger further reactions and the time required for clot formation measured. Standardised Phospholipids are required to form complexes, which activate FX and Prothrombin, which allows the test to be conducted in patient Platelet poor plasma (PPP).

The test depends not only on the contact factors and factors VIII and IX, but also on the reactions with factors X, V, Prothrombin and Fibrinogen. It is also sensitive to the presence of circulating anticoagulants (inhibitors) and Heparin.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Veno-occlusion should be avoided.

Precautions: APTT results may be affected by many commonly administered drugs and further studies should be made to determine the source of unexpected abnormal results. Oral contraceptive and Oestrogen therapy in males have been found to decrease APTT in vivo. Conversely, Heparin, Warfarin, Lupus anticoagulant and radio therapy have been found to increase APTT in vivo.

Accredited	No	No		
Method	Stago Compact Max, Stago	Sysmex CA660		
	Satellite Max SOP: H60, H56	SOP: BH05 and BH06		
Sample	Tube Type: Sodium Citrate	Tube Type: Sodium Citrate Plasma 3.2%		
Requirements	Plasma 3.2%	Temperature: 4 hours Room temperature		
	Temperature: 4 hours Room	or 2 weeks -20°C		
	temperature or 2 weeks -20°C	Miscellaneous: N/A		
	Miscellaneous: N/A	Collection: Cf. Special requirement for		
	Collection: Cf. Special	Coagulation test		
	requirement for Coagulation			
	test			
Turn Around	Mon Tue Wed Thu Fri	24h Mon Tue Wed Thu Fri		
Time - Setup	V V V V	Mon Tue Wed Thu Fri		
Schedule	24h			

eurofins 🙀

Document number: PSM	Effective date:	Page 13 of 17			
Haematology	22/09/2023	_			
Issue number: 3.02					
Title:					
Primary Sample Manual - Haematology					

	T	T		
Stability	Whole blood: 4 hours, unless centrifuged at room temperature at 1500g for 15 min, separated and the plasma frozen. Can only be thawed once. If an expected delay from collection time to receipt in the laboratory, suggest send frozen plasma. (BD Ref. VS5966 Evaluation of 0.109M BD Vacutainer® Plus Plastic and 0.105M BD Vacutainer® Glass Sodium Citrate Tubes for PT and APTT Using the Sysmex CA - 1500 Analyzer. BD, Franklin Lakes, NJ, USA June 2002; CSLI H21-A5)	Whole blood: 4 hours, unless centrifuged at room temperature at 1500g for 15 min, separated and the plasma frozen. Can only be thawed once. If an expected delay from collection time to receipt in the laboratory, suggest send frozen plasma. (BD Ref. VS5966 Evaluation of 0.109M BD Vacutainer® Plus Plastic and 0.105M BD Vacutainer® Glass Sodium Citrate Tubes for PT and APTT Using the Sysmex CA - 1500 Analyzer. BD, Franklin Lakes, NJ, USA June 2002& CSLI H21-A5)		
Units - Reference	26.0 – 40 seconds	23.4-31.3		
Ranges				
Source	Dacie and Lewis, Practical Haematology 12th edition, 2017	Coagulation reference ranges were based on values obtained by analysis of 50 samples from healthy adult plasma donors		

Document number: PSM	Effective date:	Page 14 of 17			
Haematology	22/09/2023				
Issue number: 3.02					
Title:					
Primary Sample Manual - Haematology					

BLOOD PARASITOLOGY - MALARIA

Malaria is caused by a group of related intracellular protozoan pathogens of the genus Plasmodium. These species exhibit a complex life cycle reliant on a mammalian host and anopheles mosquito vector. In the human host they are obligate intracellular pathogens infecting initially the liver in the sporozoite form. In the liver the parasites replicate and develop into merozoites which are then released into the blood stream. These infect the erythrocyte and begin a restricted life cycle. Each parasite may develop into a schizont (a cluster of infectious units which may invade further erythrocytes) or a gametocyte (the sexual form which may be transferred to the anopheles mosquito upon taking a blood meal). Re-infection of the liver does not occur.

Suspected malaria is a medical emergency. Sampling and processing of the blood sample must not be delayed if malaria is suspected. Five primary species of malaria have been identified in humans: P.falciparum, P.vivax, P.ovale P.malariae and P.knowlesi. Their geographic distribution is unique for each species.

Blood should ideally be taken direct from the patient's finger or ear & the films prepared at the bedside or in the clinic. When this is not possible blood taken into anticoagulant (EDTA) can be used. Thick & thin blood films should be made as soon as possible, certainly less than 2 hours after the EDTA blood was drawn, to minimise morphological changes in the parasites. Parasite and red cell morphology can be seriously affected if the blood has been in anticoagulation for too long.

Where there is a strong clinical suspicion if the first films are negative, blood should be taken and films made and checked at least two times over the first 24 hours and further films examined every 12 hours after that if strongly clinically indicated.

Preparation of patients:

Travel history should be recorded and any clinical details recorded on the request form.

In symptomatic patients please phone the laboratory prior to sending the sample.

Precautions: Global distribution of malaria is restricted to areas endemic to the anopheles mosquito. Latent infections of some species may occur due to hypnozoites stored in the liver. P. *knowlesi* is morphologically indistinguishable from P. *malariae* on blood film preparations.

iriuistiriguisriable	e from F. <i>maiana</i> e on blood film preparations.			
Accredited	No			
Method	Haematology – Thick & Thin Blood film & CareStart Malaria Rapydtest antigen kit (Kit Insert: APACOR CareStart RAPYDTEST- APA059 V7 04/2017) SOP: H47			
Sample	Tube Type: Whole Blood K2/K3 EDTA (Lavender cap)			
Requirements	Temperature: + 4°C Miscellanous: Observe periodicity where applicable.			
Turn Around Time – Setup Schedule	24h Mon Tue Wed Thu Fri			
Stability	Blood films Thick & thin need to be made less than 2 hours after the blood EDTA was drawn. 2 days @ 2 - 8°C (CareStart RAPYDTEST Malaria Antigen Kit)			
Units -	% parasitaemia (applicable to P. falciparum & P. knowlesi infection)			
Reference	No reference ranges applicable.			
Ranges	Genus and species reportable.			
Source	WHO Guideline: 'The Laboratory Diagnosis of Malaria'. J.W Bailey, B.J Bain, J Parker-Williams and P.Chiodini for the General Haematology Task Force of the British Committee for Standards in			
	Haematology. http://www.bcshguides.com/documents/malaria-bcsh.2005.pdf			
	Malaria Reference Laboratory. <u>www.malaria-reference.co.uk</u>			

🥸 eurofins

Document number: PSM Haematology Issue number: 3.02	Effective date: 22/09/2023	Page 15 of 17		
Title: Primary Sample Manual - Haematology				

D-DIMER

D-dimer is a degradation product of cross-linked fibrin. The D-dimer concentration is a measure of the fibrinolytic activity of plasmin in the vascular system. Elevated concentrations of D-dimer indicate increased coagulatory and fibrinolytic activity. With a normal D-dimer value, acute deep vein thrombosis and pulmonary embolisms may be ruled out with high reliability.

Preparation of patients: There is no physical preparation for the D-Dimer test.

Precautions: No modifications to change diet, medications, or activity required before this test. Phlebotomists should enquire about any blood thinners or anticoagulant medication any diseases like liver disease and rheumatoid arthritis. There are some herbs that are also able to replicate the effects of blood thinning medication.

or blood trillining i	nedication.			
Accredited	No			
Method	Stago Compact Max SOP H60			
Sample Requirements	Tube Type: Sodium Citrate 3.2%, Temperature: 15-25°C (Do not refrigerate or freeze) Miscellanous: N/A			
Turn Around Time – Setup Schedule	Same Day Mon Tue Wed Thu Fri			
Stability	8 hours @ 15-25°C			
Units - Reference Ranges	0.0-0.50 μg/mL			
Source	BD Ref. VS5966 Evaluation of 0.109M BD Vacutainer® Plus Plastic and 0.105M BD Vacutainer® Glass Sodium Citrate Tubes for PT and APTT Using the Sysmex CA - 1500 Analyzer. BD, Franklin Lakes, NJ, USA June 2002			

💸 eurofins

Document number: PSM Effective date: Page 16 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

RETICULOCYTES

The process of red blood cell production starts in the bone marrow, where cells pass through various stages of development, becoming increasingly mature. The reticulocyte is the final stage of the development of the red blood cell before full maturation. Reticulocyte is an immature red blood cell without a nucleus, having a granular or reticulated appearance when suitably stained. They are present in normal blood in very low numbers, increased numbers are maybe the product of a pathological process or could be the body's response to pregnancy, therapy with iron B12, or folate or to blood loss. Reticulocytes are not part of the full blood count so they need to be specifically requested.

Preparation of patients: There is no physical preparation for the test.

Precautions: Frozen, clotted, or grossly haemolysed samples cannot be analysed.

Accredited	No							
Method	Haematology – SYSMEX XN2000							
Sample Requirements	SOP: H57 Tube Type: Whole Blood (Lavender cap) Temperature: + 4°C Miscellanous: N/A							
Turn Around Time – Setup Schedule	24h	Mon ✓	Tue ✓	Wed ✓	Thu ✓	Fri ✓	Sat ✓	

Stability 2 days @ + 4°C

Units -
Reference
Ranges

Reference Range for both Male & Female

Age	Absolute Reference Range	Age	% Reference Range
0 - 1 day	324 - 617 x10 ⁹ /L	0 - 1 day	1.72 - 8.62%
1 - 5 days	85 - 400 x10 ⁹ /L	1 - 5 days	1.9 - 9.1%
5 days - 1mth	34.2 -724 x10 ⁹ /L	5 days - 1 mth	0.1 - 6.9%
1 - 3 mths	21.3 - 205 x10 ⁹ /L	1 - 3 mths	0.1 - 6.27%
3 - 12 mths	8.0 - 171 x10 ⁹ /L	3 - 12 mths	0.1 - 4.7%
1 - 3 yrs	55.6 - 120 x10 ⁹ /L	1 - 3 yrs	0.35 - 2.95%
3 - 7yrs	16.4 - 120.7 x10 ⁹ /L	3 - 7 yrs	0.25 - 2.57%
Adult	35.2 - 122.8 x10 ⁹ /L	Adult	0.75 - 2.7%

Source

Haematology, G. Moore, G. Knight & A. Blann, 2nd edition, Oxford 2016. The RR was derived from the Drogheda OLOL SYSMEX XN-1000 Analyser. The RR from OLOL Drogheda Our Ladys Hospital for Sick Children Crumlin, Great Ormond Street Hospital, Dacie & Lewis Practical Haematology 10th Edition and Pediatric Haematology 3rd Edition. This is based on the correlation study between OLOL hospital and Eurofins-Biomnis during validation and compatible platforms, reagents, calibrators and controls.

🧱 eurofins

Document number: PSM Effective date: Page 17 of 17
Haematology 22/09/2023
Issue number: 3.02

Title:
Primary Sample Manual - Haematology

SICKLE CELL SCREENING TEST

Sickle cell disease is an inherited condition characterised by the presence of Haemoglobin S (HB-S). Hb-S exists in a homozygous state (S/S) known as Sickle Cell Anaemia or in a heterozygous state (A/S) known as Sickle Cell Trait. Homozygous individuals (S/S) commonly exhibit symptoms of severe haemolytic anaemia and/or vascular occlusions. Heterozygous individuals (A/S) are usually asymptomatic. Hb-S may be present with other haemoglobins, such as Haemoglobin A, C or D, or with thalassemia, a condition that interferes with the synthesis of normal haemoglobin.

Under conditions of low oxygen tension, the heterozygous (A/S) form can cause erythrocytes to form the characteristic sickle-shaped tactoids. The formation of these irreversible sickled red blood cells causes the onset of the acute symptoms. Detection of both the homozygous and heterozygous condition is important so high-risk individuals can be identified and their symptoms reduced.

SICKLEDEX® kit is a qualitative solubility test for testing the presence of sickling haemoglobins in human blood. Deoxygenated Hb-S is insoluble in the presence of a concentrated phosphate buffer solution and forms a turbid suspension that can be easily visualised. Normal Haemoglobin A and other haemoglobins remain in solution under these conditions. These different qualitative outcomes allow for the detection of sickle cell disease and its traits.

SICKLEDEX uses Saponin to lyse the red blood cells. Sodium Hydrosulfite then reduces the released haemoglobin. Reduced Hb-S is insoluble in the concentrated phosphate buffer and forms a cloudy turbid suspension. Other sickling haemoglobin subtypes may also give a positive result.

Preparation of patients: There is no physical preparation for the test.

Precautions: Frozen, clotted, or grossly haemolysed samples cannot be analysed.

Precautions: From	zen, clotted, or grossly haemolysed samples cannot be analysed.		
Accredited	No		
Method	Haematology- qualitative solubility test for testing the presence of sickling haemoglobins SOP: H53		
Sample Requirements	Tube Type: Whole blood EDTA Temperature: + 4°C Miscellaneous: N/A		
Turn Around Time – Setup Schedule	24h Mon Tue Wed Thu Fri √ √ √ √ √ ✓		
Stability	3 days @ + 4°C		
Result	Positive or negative		
Source	Sickledex kit insert, Streck – 350512-13, 05-2016.		

🙀 eurofins